Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Spanish court upholds Pfizer’s Lipitor patent
The Commercial Court of First Instance Number 4 in Barcelona, which issued the ruling, found a second patent covering a stabilized formulation that includes atorvastatin is invalid. The
The Commercial Court of First Instance Number 4 in Barcelona, which issued the ruling, found a second patent covering a stabilized formulation that includes atorvastatin is invalid. The
The entire transaction is valued at about $790 million, comprised of the 24.4 million company shares that were outstanding as of April 28 as well as $30.50 each
Eliezer Zomer, executive vice president, product development & manufacturing, Pro-Pharmaceuticals, explained: “Biliary tract and gall bladder cancers are challenging to treat, especially after failure of surgery which is
Previous research has indicated that abnormal levles of lipids are associated with HIV patients on antiretroviral treatment. Abnormal lipid levels could lead to an increased risk of adverse
SMi stockholders could also receive a maximum of $15 million in additional consideration, payable in either cash or shares of CTI common stock, upon the achievement of certain
The Swiss drug maker compared the efficacy and safety of Actemra monotherapy to the standard methotrexate treatment in rheumatoid arthritis patients. After 24 weeks of treatment, the Actemra
The FDA is now requesting results from a one-year safety trial on how the drug affects these organs. The decision stalls Wyeth’s plans to market Pristiq as the
This was the first of several regularly scheduled reviews by the data safety monitoring board (DSMB) that will occur over the duration of the trial. The purpose of
The randomized, double-blind, placebo-controlled trial, conducted with the company’s novel sustained release (SR) formulation of zonisamide paired with bupropion SR, evaluated various ratios of bupropion and zonisamide in
The company says ICA-105665 is an activator of subtypes of KCNQ ion channels, which are attractive targets for the treatment of epilepsy based on their function and genetic